In their year-end list of top scientific achievements and the people who made them, both Science and Nature have included the fight against “the obesity epidemic.” Science named GLP-1 drugs as its Breakthrough of the Year, while Nature included Svetlana Mojsov in its 2023 list of the year’s most important investigators. Mojsov is research associate professor at The Rockefeller University and was an early contributor to understanding the metabolic role of GLP. Read More
Autologous chimeric antigen receptor (CAR) T-cell therapy has been one of the most recent successes in cancer treatment, but limitations, such as manufacturing, costs or antigen escape in therapies directed against only one target that leads to resistance, highlight the need for new approaches. Classical natural killer T (NKT) cells engineered to express CARs constitute a novel type of allogeneic therapy that does not require T-cell receptor (TCR) gene editing, thus avoiding graft-vs.-host disease (GVHD). Read More
Saniona AB has reported that it has selected SAN-2355 as the first clinical candidate from its Kv7 epilepsy program and is poised to advance it into preclinical development. Read More
Innovent Biologics Inc. and Sanegene Bio USA Inc. (Sanegenebio) have announced they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension. Read More
Researchers from Bridgebio Pharma Inc. recently presented BBO-10203, a first-in-class, orally bioavailable, covalent small-molecule candidate designed to inhibit RAS-driven PI3Kα activity without affecting glucose metabolism. Read More
Asieris Pharmaceuticals Co. Ltd. announced that it has received approval to commence phase I clinical trials in Australia of its novel antibacterial drug, APL-2301 (ASN-1733, MET-102), under development for the treatment of Acinetobacter baumannii infections. Read More
Aeovian Pharmaceuticals Inc. has disclosed new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of neurodegenerative diseases. Read More
PI3Kα H1047R accounts for one-third of all PI3Kα mutations and is associated with treatment resistance to targeted therapies in breast cancer treatment. In addition, treatment with selective PI3Kα inhibitors often results in significant adverse events such as hyperglycemia due to on-target toxicity. Read More
Olix Pharmaceuticals Inc. has received approval from the Alfred Human Research Ethics Committee (HREC) in Australia to conduct a phase I clinical trial of drug candidate OLX-75016 for the treatment of nonalcoholic steatohepatitis (NASH). Read More
Eli Lilly & Co. has patented new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of Aicardi-Goutieres syndrome, dermatomyositis, systemic lupus erythematosus and lupus nephritis. Read More
Researchers from Sichuan University and Chengdu Normal University have reported the discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer (TNBC). Read More
Ono Pharmaceutical Co. Ltd. has entered into a discovery collaboration agreement with Evqlv Inc. to generate novel antibodies against multiple targets selected by Ono, for the development of innovative antibody drugs. Read More
Ankh Life Sciences Ltd. have identified polycyclic compounds reported to be useful for the treatment of bacterial, fungal and viral infection. Read More
Senti Biosciences Inc. has received clearance of its IND application from the FDA for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33- and/or FLT3-expressing hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome, while sparing healthy bone marrow cells. Read More
Fused pyrimidine compounds acting as menin (MEN1)/MLL interaction inhibitors have been described in a Biomea Fusion Inc. patent and reported to be useful for the treatment of cancer, osteoporosis, autoimmune and inflammatory diseases, among others. Read More
A team of researchers at Monash University, Swiss Tropical & Public Health Institute and the University of Nebraska have prepared aryl hydantoin compounds for the treatment of schistosomiasis. Read More
Fauna Bio Inc. has signed a multi-year agreement with Eli Lilly and Co. to apply Fauna’s Convergence artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity. Read More
Are you trying to stay on top of developments in CAR T therapies? Drug resistance? Emerging compounds? Updates from certain regulatory agencies? Want to be the first to learn about new biomarkers or business deals? You can still find these articles in the daily BioWorld e-newsletters or on the website, but if you’re laser-focused on a specific topic, we have a way to highlight the news you need as it happens, whether we’ve published a full-length feature story or a brief update. You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Happy holidays! Read More
